LLY — Eli Lilly and Company

Summary of Eli Lilly's Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Full-Year Revenue: $65.2 billion, up 45% from 2024.
• Earnings Per Share (EPS): $24.21, an 86% increase year-over-year.
• Q4 Revenue: $18.1 billion, a 43% increase compared to Q4 2024.
• Gross Margin: 83.2%, consistent with Q4 2024.
• R&D Expenses: Increased by 26% due to investments in the portfolio.
• Marketing, Selling, and Administrative Expenses: Increased by 29% to support launches.
• Non-GAAP Performance Margin: 47.2%, up 4.2 percentage points from Q4 2024.
• Dividends and Share Repurchases: $1.3 billion in dividends and $1.5 billion in share repurchases.

2. Strategic Updates and Business Highlights

• Product Launches: Successful launches of Inlureo, new indications for Omvo and Jayperca, and international rollouts of Mounjaro and Kisanlo.
• Pipeline Development: Over 25 positive phase three trial results, including submissions for Orforglipron for obesity in the US and 40 other countries.
• Manufacturing Expansion: Significant investments in new manufacturing sites in the US and Europe, with a commitment of over $55 billion since 2020.
• AI Investments: Collaboration with NVIDIA to accelerate drug discovery through AI technology.
• Direct-to-Patient Platform: Engaged 1 million patients in 2025, with Zepbound self-pay vials representing one-third of new patient starts.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $80 billion and $83 billion, a 25% increase from 2025.
• EPS Guidance: Anticipated between $33.50 and $35.
• Market Dynamics: Continued growth in incretin analogs, with expectations for Orforglipron to launch in 2026 and expand market access through Medicare.
• Pricing Pressure: Anticipated price declines in the low to mid-teens due to government agreements and Medicaid pricing adjustments.

4. Bad News, Challenges, or Points of Concern

• Pricing Pressures: Lower realized prices expected to impact revenue growth, particularly in the US market.
• Market Access Challenges: Potential reductions in Medicaid access due to state-level changes.
• Competition: Increasing competition in the obesity treatment market, particularly with new entrants.
• Mature Product Performance: Late lifecycle products like Trulicity and Verzenio expected to remain flat or decline.

5. Notable Q&A Insights

• Orforglipron Launch Metrics: Expectations for market expansion rather than cannibalization, with a focus on patient satisfaction and real-world efficacy.
• International Approval Timelines: Most international launches anticipated for 2027, with some exceptions for late 2026.
• Medicare Volume Ramp: Anticipated to begin no later than July 1, 2026, with a bolus of Medicare patients moving into the market.
• Combination Therapies: Interest in exploring combination therapies in immunology and oncology, leveraging the benefits of incretins.
• Cash Pay Dynamics: Discussion on the long-term implications of cash pay dynamics and how it may affect market share retention amidst increasing competition.

Overall, Eli Lilly reported strong financial performance in 2025, with significant growth in revenue and EPS, while also outlining ambitious plans for 2026 amidst challenges related to pricing pressures and competition in the obesity market.